Nov 06,2023

Can Collaborative Partnerships with Industry Drive Much-Needed Improvements in Lung Cancer Outcomes in the UK?

Lung cancer is the leading cause of cancer-related deaths in the UK, with 35,000 fatalities annually, posing a significant healthcare challenge in terms of costs and patient care. The introduction of advanced technology presents an opportunity to revolutionize patient pathways for quicker access to diagnostics and treatment. To address these issues, AstraZeneca's initiative, PATHFINDER, aims to optimize lung cancer pathways, aligning with NHS goals for timely diagnoses and treatment. It utilizes collaborations with experts and cutting-edge technology to streamline pathways, accelerate diagnoses, and increase curative treatment rates. Partners like IQVIA, Qure.ai, and Clinithink aid in auditing hospital sites, using AI solutions to process vast medical records swiftly and develop predictive models for early risk identification. This short interview with Vicky Heaton, Lung Cancer Franchise Head at AstraZeneca and Dr. Neal Navani, Consultant Respiratory Physician at University College London Hospitals, discuss the potential of the PATHFINDER initiative in identifying issues within the lung cancer pathway.

#ai/software

#clinical decision support

View Analyst & Ambassador Comments
Go to original news
Nov 03,2023 TOP STORY

Aidence, Incepto, and Thirona launch joint clinical solution to support the expansion of lung cancer screening in Europe

MedTech companies Aidence, Incepto, and Thirona jointly introduce a comprehensive AI-powered software package for lung cancer screening and the analysis of emphysema. The companies aim to support healthcare providers in accelerating lung cancer screening roll-out across Europe with a suite of integrated artificial intelligence (AI) solutions and reporting capabilities that are seamlessly integrated in the radiology workflow. Netherlands-based Aidence and Thirona provide leading AI clinical applications for lung disease detection and management on chest CT scans. Aidence’s Veye Lung Nodules automatically detects, measures, classifies, and tracks the volume growth of pulmonary nodules, possible early signs of lung cancer. Thirona is specialized in advanced analysis of thoracic CT images providing high-precision quantification of anatomical lung structures for a wide range of diseases and pathologies.

COLLABORATION PARTNERSHIP

#product & service

#ai/software

#clinical decision support

View Analyst & Ambassador Comments
Go to original news
Nov 01,2023 TOP STORY

IMVARIA Enters into Know-how Agreement with Mayo Clinic to Improve the Understanding of Cancer through AI Digital Biomarkers

IMVARIA Inc., a health tech company pioneering AI-driven digital biomarker solutions, announced a collaboration through a know-how agreement with Mayo Clinic to develop AI designed to significantly improve the analysis and understanding of cancer, beginning with lung cancer. With its unique platform, IMVARIA’s team of experts specializes in developing and advancing digital biomarkers to enable better patient outcomes. The collaboration brings together IMVARIA’s engineering expertise in digital biomarkers with Mayo Clinic’s know-how and data assets as part of the Validate pillar of Mayo Clinic Platform. The large-scale datasets will allow for comprehensive and reliable training of AI “brains” to discover and validate clinically relevant software-only biomarkers for cancer, analyzing complex text, numeric values, and images.

COLLABORATION PARTNERSHIP

#r&d

#ai/software

#digital biomarkers

View Analyst & Ambassador Comments
Go to original news
Aug 23,2023

VOCxi and S3 partner to develop lung cancer detection and monitoring tech

VOCxi Health and S3 Connected Health have entered a partnership agreement to develop and market a lung cancer detection and monitoring device. VOCxi currently has a breath analyser device, BreathEZ, which is designed to detect lung cancer by analysing volatile compounds in the exhaled air. The device is supposed to help in early detection of lung cancer, thereby, improving survival rates for affected patients. S3 Connected has a digital health platform, Affinal, which is designed to better integrate digital services. As per the partnership agreement, VOCxi plans to leverage S3’s Affinal platform to create a custom mobile application and a cloud-based solution for BreathEZ. The companies also plan on expanding the usage of BreathEZ to other disease indications.

COLLABORATION PARTNERSHIP

#r&d

#mobile app

#connected device

View Analyst & Ambassador Comments
Go to original news
Oct 05,2023 TOP STORY

Computer Model Predicts Who Needs Lung Cancer Screening

A machine learning model equipped with only data on people's age, smoking duration and the number of cigarettes smoked per day can predict lung cancer risk and identify who needs lung cancer screening, according to a new study publishing October 3rd in the open access journal PLOS Medicine by Thomas Callender of University College London, UK, and colleagues. In the new study, researchers used data on 216,714 ever-smokers from the UK Biobank cohort and 26,616 ever-smokers participating in the US National Lung Screening trial to develop new models of lung cancer risk. The researchers tested the new model on a third set of data, from the US Prostate, Lung, Colorectal and Ovarian Screening Trial. The model predicted lung cancer incidence with an 83.9% sensitivity and lung cancer deaths with an 85.5% sensitivity.

CLINICAL STUDY

#ml

View Analyst & Ambassador Comments
Go to original news
Sep 25,2023 TOP STORY

ASTRAZENECA AND INSTITUT KANSER NEGARA PARTNER TO INTRODUCE AI TECHNOLOGY FOR LUNG SCREENING

In conjunction with Institut Kanser Negara's (IKN) 10th anniversary, AstraZeneca announced its collaboration to accelerate digitalisation in healthcare by introducing Artificial Intelligence (AI) x-ray technology into early lung screening at government clinics and hospitals under the Projek Saringan Awal Paru-Paru (SAPU) programme. Projek SAPU aims to act as a catalyst to encourage the adoption of AI x-ray screening by other government healthcare facilities, fostering a broader embrace of early screening for lung abnormalities as well as advancing research efforts in lung care. This initiative is part of AstraZeneca's early AI-powered lung cancer screening under its flagship Lung Ambition Alliance programme, which was first rolled out in 2021 at the primary care level with private clinics. A year later, AstraZeneca further expanded its early AI lung cancer screening programme by partnering with three (3) private tertiary hospitals to facilitate patient referral from the clinics, for further diagnosis using a low-dose computed tomography (LDCT) scan.

COLLABORATION PARTNERSHIP

#institution

#ai/software

View Analyst & Ambassador Comments
Go to original news
Aug 23,2023

How real-world data is enhancing our understanding of lung cancer recurrence

A collaborative team from COTA and AstraZeneca used curated RWD to investigate factors affecting disease-free survival and recurrence patterns in early-stage non-small cell lung cancer (NSCLC) patients. The researchers examined patterns of care, disease-free survival, and patient characteristics using real-world data from over 700 early-stage NSCLC patients diagnosed between 2013 and 2018. They found that patients with more advanced disease stages, genetic mutations (EGFRm positive), and those who only had surgical resection had shorter disease-free survival times. Distant/metastatic recurrence was common among all patients. The study confirmed that disease stage at diagnosis influences disease-free survival and supported the idea that adjuvant therapies improve disease-free survival compared to surgery alone.

COLLABORATION PARTNERSHIP

#data & technology

#rwd

View Analyst & Ambassador Comments
Go to original news
Subscribe to LUNG CANCER